A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

NCT ID: NCT03969992

Last Updated: 2025-08-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

261 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-04

Study Completion Date

2024-08-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Part I Primary Objective To determine an optimal dose of AeroFact administered by nasal continuous positive airway pressure (nCPAP) versus stand of care in reducing the rate of intubation/cannulation and bolus surfactant instillation in the first 7 days after birth.

Part II Primary Objective To evaluate pulmonary outcomes and respiratory utilization at 3, 6, 9, and 12 months post-menstrual age (PMA)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Distress Syndrome in Premature Infant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Partially Blinded, Randomized, Parallel-Group Dose Ranging
Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Masking within active arms

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

nCPAP alone

Standard of Care (nasal continuous positive airway pressure-nCPAP) with instilled bolus surfactant when medically necessary

Group Type OTHER

nCPAP

Intervention Type OTHER

nCPAP (nasal continuous positive airway pressure) alone

Drug: Low Dose AeroFact

AeroFact-low dose SF-RI 1

Group Type EXPERIMENTAL

AeroFact

Intervention Type DRUG

Aerosolized SF-RI 1

Drug: High Dose AeroFact

AeroFact-high dose SF-RI 1

Group Type EXPERIMENTAL

AeroFact

Intervention Type DRUG

Aerosolized SF-RI 1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AeroFact

Aerosolized SF-RI 1

Intervention Type DRUG

nCPAP

nCPAP (nasal continuous positive airway pressure) alone

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SF-RI 1

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Parental consent obtained prior to study procedures being performed (pre-natal consent is allowed)
2. 26 0/7 to 30 6/7 weeks of gestational age
3. Weight \<2.0 Kg
4. Respiratory Severity Score (RSS) 1.4-2.0

Exclusion Criteria

1. Apgar score less than or equal to 5 at five minutes after birth
2. Need for chest compressions or administration of epinephrine or bicarbonate in the delivery room
3. Premature rupture of membranes (PROM) \> 14 days
4. Need for intubation and/or mechanical ventilation prior to enrollment
5. Active pneumothorax requiring chest tube
6. Significant congenital anomaly, chromosomal abnormality
7. Concomitant treatments with inhaled nitric oxide
Minimum Eligible Age

26 Weeks

Maximum Eligible Age

31 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aerogen Pharma Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Durand, MD

Role: STUDY_DIRECTOR

Aerogen Pharma Corp

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Site Status

Alta Bates Summit

Berkeley, California, United States

Site Status

Children's Hospital Orange County

Orange, California, United States

Site Status

University of Colorado

Aurora, Colorado, United States

Site Status

University of Florida Health

Jacksonville, Florida, United States

Site Status

Wolfson Children's Hospital

Jacksonville, Florida, United States

Site Status

South Miami Hospital

Miami, Florida, United States

Site Status

Advent Health

Orlando, Florida, United States

Site Status

Winnie Palmer Hospital

Orlando, Florida, United States

Site Status

Northside Hospital Atlanta

Atlanta, Georgia, United States

Site Status

University of Illinois

Chicago, Illinois, United States

Site Status

Hospital of South Bend

South Bend, Indiana, United States

Site Status

University of Louisville

Louisville, Kentucky, United States

Site Status

Barbara Bush Medical Center

Portland, Maine, United States

Site Status

University of Maryland

Baltimore, Maryland, United States

Site Status

Holy Cross Hospital

Silver Spring, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Children's and Women's (C & W) Mott Hospital

Ann Arbor, Michigan, United States

Site Status

Children's Health Care d/b/a Children's Minnesota

Minneapolis, Minnesota, United States

Site Status

University of Minnesota Masonic Children's Hospital

Minneapolis, Minnesota, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

University of Mississippi

Jackson, Mississippi, United States

Site Status

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Maimonides Hospital

Brooklyn, New York, United States

Site Status

Mount Sinai Kravis Children's Hospital

New York, New York, United States

Site Status

Columbia University Medical Center/New York Presbyterian Hospital

New York, New York, United States

Site Status

NY Presbyterian Morgan Stanley Children's Hospital-Columbia

New York, New York, United States

Site Status

West Chester Medical Center-Maria Fareri Children's Hospital

Valhalla, New York, United States

Site Status

Levine Children's Hospital

Charlotte, North Carolina, United States

Site Status

Grant Hospital

Columbus, Ohio, United States

Site Status

Texas Health-Methodist Harris

Fort Worth, Texas, United States

Site Status

Women's Hospital of Texas

Houston, Texas, United States

Site Status

Children's Hospital of San Antonio (CHofSA)

San Antonio, Texas, United States

Site Status

Methodist Children's Hospital

San Antonio, Texas, United States

Site Status

North Central Baptist Hospital

San Antonio, Texas, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

University of Washington

Seattle, Washington, United States

Site Status

IWK Hospital

Halifax, Nova Scotia, Canada

Site Status

The Ottawa Hospital

Ottawa, Ontario, Canada

Site Status

Mt. Sinai Hospital

Toronto, Ontario, Canada

Site Status

CHU de Québec-Université Laval

Québec, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APC-AF-CLN-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Preterm Infant Inhaled Albuterol Dosing
NCT02447250 COMPLETED PHASE4